Jon's Licence Portfolio
Novel compounds with dual DNA-PK/AKT inhibitor activity for the treatment of platinum-resistant cancers.
Use of short/medium chain fatty acids, including valerate and bile salt hydrolase (BSH) for the treatment and prevention of recurrent C. difficile infection
An improved SARS-CoV-2 spike protein subunit (S1) antigen and two exceptional ELISA assay formats for highly specific and sensitive serological detection and measurement of antibodies to SARS-CoV-2
18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs).
A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity
A simple, whole blood 2-gene expression signature that distinguishes bacterial infection from both viral infection and childhood inflammatory diseases.
DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway
A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging
A tool for predicting Alzheimer’s Disease (AD) with greater accuracy than conventional methods.
A tool for predicting risk profile in patients with pre-existing cardiac dysfunction with greater accuracy than the current gold standard
Patient Metabolic profiling for personalised medicine.
Gene expression for tuberculosis diagnosis
Small molecule inhibitors for treatment of solid tumours